AAO 2023: How Neurotech's encapsulated cell therapy NT-501 targets ocular disease

News
Video

At AAO 2023, Rich Small, CEO of Neurotech, spoke with our team about the company's development of encapsulated cell therapy, NT-501

Rich Small, CEO of Neurotech, spoke with the team at Ophthalmology Times about the company's development of encapsulated cell therapy, NT-501, at this year's American Academy of Ophthalmology meeting.

Video Transcript

Editor's note - This transcript has been edited for clarity.

Rich Small:

Hi, I'm Rich Small, CEO of Neurotech. It's my pleasure to be here to give you an update on Neurotech. We're developing a really cool technology, it's called encapsulated cell therapy. And in encapsulated cell therapy, we take RPE cells, we genetically modify them to release a therapeutic factor. And the cells are encapsulated in a semipermeable membrane, which allows these therapeutic factors to actually release into the back of the eye, while also allowing nutrients to continuously nourish these cells. And then furthermore, it also prevents the immunoresponse from occurring. So actually, a lot of really cool elements to this technology.

Our first ECT product that we're in clinical development with is called NT-501. And what NT-501 does, is it releases the neurotrophic factor CNTF. And what CNTF is, it's a well-known neuroprotective of keeping, keeping the photoreceptors healthy. And our first clinical, our most advanced clinical program that we're developing NT-501 for is for the orphan disease called macular telangiectasia, MacTel. And late last year, we actually just completed two Phase III studies in MacTel. And studying the, the therapy against the disease itself, and what we found, the results were the treated group was significantly slowed down the progression of disease versus control. So it's something very exciting for us. And we're very excited about our technology.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
Related Content
© 2025 MJH Life Sciences

All rights reserved.